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Graft-versus-host disease (GVHD) has no therapeutic beneﬁt after hematopoietic cell transplantation (HCT)
for patients with acquired aplastic anemia (AA), and its prevention is highly desirable. We designed a con-
ditioning regimen using an intermediate dose of alemtuzumab (50 to 60 mg) and describe our institutional
experience of 41 patients who underwent HCT for AA. The median age at HCT was 37 years (range, 17 to 59).
The conditioning regimen was high-dose cyclophosphamide (n ¼ 9) or ﬂudarabine based (n ¼ 32). Additional
GVHD prophylaxis was with cyclosporine. With a median follow-up of 3.6 years, overall survival at 3 years
was 85%. Survival in patients <40 years and 40 years was 96% and 67%, respectively (P ¼ .04). Graft failure
occurred in 4 (10%) patients; 2 primary and 2 secondary. The cumulative incidences of acute (grades 1 to 2)
and chronic GVHD were 27% and 15%, respectively. No patients developed grade 3 to 4 acute GVHD or severe
chronic GVHD. The following viral complications were frequent: cytomegalovirus reactivation (79%), herpes
simplex (18%), varicella zoster (25%), and BK virus hemorrhagic cystitis (8%). The majority of patients had no
signiﬁcant long-term health issues. This intermediate-dose alemtuzumab-based conditioning regimen results
in excellent survival with a favorable impact on GVHD and long-term health outcomes, but close monitoring
for viral complications is important.
Crown Copyright  2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow
Transplantation. All rights reserved.INTRODUCTION monoclonal antibodies [8,9]. The main concerns with the
The goals of hematopoietic cell transplant (HCT) in
acquired aplastic anemia (AA) are sustained hematopoietic
recovery, minimal regimen-related toxicities, and minimal
graft-versus-host disease (GVHD). The most commonly
used conditioning regimen in AA is cyclophosphamide and
antithymocyte globulin (ATG) with cyclosporine and meth-
otrexate as GVHD prophylaxis [1]. In addition, total body
irradiation is often used for unrelated donor transplantations
for patients with AA [2-4]. With these strategies, 30% to 40%
of patients with AA develop acute and chronic GVHD,
resulting in morbidity, mortality, and poor quality of life
[1,3,5-7]. Unlike its effect in hematologicmalignancies, GVHD
has no therapeutic beneﬁt in patients with AA, and preven-
tion of GVHD is one of the most desirable goals of HCT in AA.
Previous studies reported a favorable effect on acute and
chronic GVHD in HCT for AA using in vivo anti-CD52edgments on page 1727.
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14.06.033use of anti-CD52 antibodies include the risk of graft failure
and the increased risk of infectious complications [10-12]. In
addition to using different dosing schedules, previous
studies used a higher dose of anti-CD52 antibodies (75 to 100
mg) [8,9,13]. There is a suggestion that a lower dose of
alemtuzumab may result in a lower risk of infectious com-
plications and faster immune reconstitution [14].
To optimize the use of alemtuzumab in HCT for AA at
PrincessMargaret Cancer Centre, we designed a conditioning
regimen with an intermediate dose of alemtuzumab (50 to
60mg). We previously published preliminary outcomes of 17
patients treated with alemtuzumab-based GVHD prophy-
laxis [13,15]. This study reports on outcomes of an additional
24 patients, with updated follow-up on previously reported
patients.
METHODS
Patients
A total of 41 consecutive patients who received HCT for AA between
January 2005 and August 2013 at the Princess Margaret Cancer Center,
Toronto, Canada were included in this study. Data were obtained from a
blood and marrow transplantation database, and additional informationehalf of American Society for Blood and Marrow Transplantation. All rights reserved.
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Health Network-Research Ethics Board and Cancer Registry Data Access
Committee approved this study.
Eligibility for Transplantation
Patients with severe AA (SAA) <40 years, and having a matched sibling
donor (MSD) were offered upfront transplantation. The upper age limit for
upfront therapyusingMSD transplantation for patientswithSAAwas increased
to 60 years in 2010. Patients with nonsevere AA (NSAA) were offered trans-
plantation after failure of immunosuppressive therapy (IST) using a related or
unrelated donor. Patients who only had a mismatched related donor (up to 1
antigen mismatch) or matched unrelated donor were eligible for trans-
plantation if they were refractory to or had relapsed after ATG-containing IST.
Graft Source
Although the preferred source of stem cells was bone marrow (BM),
peripheral blood grafts were accepted, based on the donor’s choice. Thirty-
four (83%) patients received BM grafts and 7 (17%) received peripheral blood
grafts.
Conditioning Regimen
Between 2005 and 2009, the institutional standard of care for AA pa-
tients <40 years with an MSD was conditioning with high-dose cyclo-
phosphamide (50 mg/kg  4 days from days 5 to 2) with alemtuzumab
50 mg (10 mg, 20 mg, 20 mg on days 8, 7, and 6 respectively) (n ¼ 9,
23%), and those 40 years with an MSD or an MUD regardless of age
received ﬂudarabine (30mg/m2 4 days from days5 to2) with low-dose
cyclophosphamide (10 mg/kg  4 days from days 5 to 2) and alemtu-
zumab 60 mg (30 mg  2 days on days 7 and 6) (Flu-Cy-Cam) (n ¼ 28,
70%). In 2009, Flu-Cy-Cam became our institutional standard of care for all
patients with AA receiving HCT (see Appendix in Supplementary Data for
the complete protocol). Busulfan replaced low-dose cyclophosphamide in
the Flu-Cy-Cam regimen in 3 patients included in this study. One of these
patients had monosomy 7, with BM biopsy ﬁndings consistent with AA. The
other 2 patients had SAA and symptomatic hemolytic paroxysmal nocturnal
hemoglobinuria, and these 2 patients also received 200 cGy total body
irradiation as a single fraction.
In the ﬁrst 10 (25%) patients, alemtuzumab was used as an i.v. infusion;
however, in 2006, we changed our institutional practice to subcutaneous
(SC) alemtuzumab because of evolving data on its improved side effect
proﬁle [16-18] and, therefore, the subsequent 31 (75%) patients received SC
alemtuzumab. Premedication for alemtuzumab (30 minutes to 1 hour
before) included diphenhydramine 50 mg, acetaminophen 650 mg, and
dexamethasone 20 mg orally.
GVHD Prophylaxis
Cyclosporin (CsA) was used for GVHD prophylaxis at a dose of
2.5 mg/kg/day i.v. every 12 hours, starting on day 1, titrated to therapeutic
trough levels between 200 and 400 mg/L. When patients were able to
tolerate oral medications, the i.v. dose was converted to the oral route. Slow
CsA tapering was initiated at 6 months after HCT unless mixed chimerism or
ongoing GVHD necessitated continuation of IST. Two patients received
tacrolimus (titrated to therapeutic levels of 10 to 20 ug/L) instead of CsA
because of a history of gum enlargement with CsA. One patient received
mycophenolate mofetil instead of calcineurin inhibitors because of end-
stage kidney disease at time of HCT [19].
Deﬁnitions
The burden of comorbidities was calculated using the HCT comorbidity
index (HCT-CI) [20]. Performance status was assessed using the Karnofsky
performance score.
The day of stem cell infusion was deﬁned as day 0. Dates of neutrophil
and platelet recovery were deﬁned as the ﬁrst of 3 consecutive days of an
unsupported absolute neutrophil count .5  109/L and unsupported
platelet count20 109/L, respectively. Lymphocyte recoverywas deﬁned as
the ﬁrst of 3 consecutive days of an absolute lymphocyte count of .5 109/
L. Patients were evaluable for engraftment if they survived >21 days after
HCT. Primary graft failure was deﬁned as the absence of absolute neutrophil
count of .5  109/L on 3 consecutive days after 6 weeks and secondary
graft failure was deﬁned as recovery followed by recurrent pancytopenia
with a hypocellular BM in the absence of severe GVHD. Time-to-RBC and
platelet transfusion independence were deﬁned as the time from the date of
HCT to the last date of transfusion for each.
Regimen-related toxicities were evaluated from the start of condition-
ing therapy until 6 weeks after HCT, deﬁned according to the Bearman’s
criteria [21].
Patients who survivedmore than 21 and 100 days were evaluable for the
occurrence of acute and chronic GVHD, respectively. Acute and chronicGVHD were graded according to modiﬁed Gluckberg’s [22] and National
Institutes of Health consensus criteria [23], respectively.
Bacterial and viral infectionswere basedon culture andPCR, respectively.
Invasive fungal infections were deﬁned as per European Organization for
Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
criteria [24].
Supportive Care
All patients received antibacterial, antiviral, and antifungal prophylaxis.
Antibacterial prophylaxis with ciproﬂoxacin 500 mg twice daily orally was
given until neutrophil engraftment. Antipneumocystis prophylaxis was initi-
ated at the time of hospital discharge and consisted of oral cotrimoxazole 3
times per week orally or inhaled pentamidine 300 mg monthly (if allergic or
intolerant to cotrimoxazole) and continued to 1 year after HCTor longer, if the
patient was still on IST. Antieherpes simplex virus (HSV) prophylaxis with
acyclovir 400mgoncedaily orallywasgiven for 3months. All patients received
antifungalprophylaxiswith itraconazole suspension (200mgorally twicedaily
for 3 months) until January 2009, after which there was a change in our
institutional practice to i.v.micafunginduring the hospital stay and a switchon
discharge to oral posaconazole suspension 200mg 3 times a day for 3months.
Routine surveillance of cytomegalovirus (CMV) viremia was performed on a
weekly basis for theﬁrst 100 days and subsequently on clinic visits up to 1 year
or according to clinical need. Thiswas done using pp65 antigenemia until 2011
and, thereafter, this was performed using PCR. Ganciclovir was used as pre-
emptive treatment in patients testing positive for CMV viremia. Pulmonary
function tests (PFTs) were routinely performed at baseline, 4 and 12 months
after HCT, and annually thereafter. Hormone proﬁles including sex hormones,
prolactin, and thyroid function tests were also done annually.
Chimerism and Disease Monitoring
Chimerism studies were performed on whole blood by short tandem
repeat (STR)-PCR analysis. Testing was carried out at 30, 60, and 120 days
after HCT routinely, and according to clinical need thereafter. Donor cells
90% were considered as predominantly donor chimerism (PDC) and <90%
as mixed chimerism (MC). Declining donor chimerismwas deﬁned as a 10%
decrease in donor chimerism on 2 consecutive measurements. In cases of
MC, an increase in the intensity of IST was attempted.
Statistical Methods
Categorical variables were summarized with counts and percentages
and continuous variables with medians and ranges or standard deviations,
as appropriate. Time-to-reach hematologic endpoints were calculated
using primary engraftment failure and death as competing endpoints.
The incidence of infection was calculated using the cumulative incidence
method with death and second HCT as a competing end point. The proba-
bility of overall survival (OS) was calculated with the Kaplan-Meier method.
Univariate analysis was performed on OS using binary clinical factors with
Kaplan-Meier curves and log-rank tests. Because of the small number of
events, a multivariate analysis was not performed. All analysis was per-
formed using R Version 3.0.1 (R Development Core Team).
RESULTS
Baseline patient-, disease-, and transplantation-related
characteristics are summarized in Table 1. The median age
at HCTwas 37 years (range,17 to 59). Themajority of patients
had SAA: 12 (29%) very severe AA,19 (46%) SAA, and 10 (24%)
NSAA. Patients with NSAA had failed IST and were trans-
fusion dependent. Donors were HLA MSD in 29 (70%) and
MUD in 12 (30%). Median follow-up of survivors was 3.6
years (range, .13 to 7.9).
Side Effects of i.v. and SC Alemtuzumab
Side effects of i.v. alemtuzumab (n ¼ 10) were infusion-
related rigors/chills (n ¼ 6, 60%), fever (n ¼ 4, 40%), gener-
alized skin rash (n¼ 3, 30%), chest tightness (n ¼ 1, 10%), and
hypotension (n ¼ 1, 10%). With SC alemtuzumab (n ¼ 31),
side effects were self-limiting erythema at injection site
(n ¼ 26, 84%), generalized skin rash (n ¼ 3, 10%), and fever
(n ¼ 2, 6%). None of the patients discontinued alemtuzumab
because of side effects.
Regimen-related Toxicities
The majority of patients tolerated the conditioning well.
None of the patients had grade 3 toxicities. Bearman grade 1
Table 1
Patient, Disease, and Transplantation Characteristics
Characteristic Value
No. of patients 41
Age at HCT, median (range), yr 37 (17-59)
<40 25 (61)
40 16 (39)
Gender
Female 23 (56)
Male 18 (44)
Disease etiology
Idiopathic 30 (73)
Chemical/drug exposure 4 (10)
Hepatitis 4 (10)
Pregnancy 3 (7)
Disease severity
Very severe AA 12 (29)
SAA 19 (46)
NSAA 10 (24)
Paroxysmal nocturnal hematuria clone
Negative 25 (61)
Positive 16 (39)
Cytogenetics
Normal 26 (63)
Failed/unavailable 14 (34)
Monosomy 7 1 (2)
Prior IST
None 20 (49)
1 course 11 (27)
2 courses 10 (24)
HCT-CI score
0/1 33 (80)
2/3 8 (20)
Performance score at HCT
80% 39 (95)
<80% 2 (5)
Time to HCT
6 mo 26 (63)
<6 mo 15 (37)
Donor type
MSD 6/6 29 (71)
MUD 12 (29)
10/10 11 (28)
9/10 (antigen DQ mismatch) 1 (2)
Female donor to male recipient 8 (20)
Graft source
BM 34 (83)
PB 7 (17)
ABO mismatch
Major 9
Minor 10
None 22
Recipient/donor CMV status
Negative/negative 16 (39)
All others 25 (61)
Conditioning regimen
CY(4) 9 (22)
FLU(30) þ CY(40) 29 (71)
FLU(4) þ BU(2) 1 (2)
FLU(4) þ BU(2) þ TBI 200 2 (4)
GVHD prophylaxis
Alemtuzumab þ cyclosporine 37 (90)
Alemtuzumab þ tacrolimus 3 (7)
Alemtuzumab þ mycophenolate 1 (2)
Alemtuzumab dose
60 mg 35 (85)
50 mg 6 (15)
Alemtuzumab route of administration
Subcutaneous 31 (76)
Intravenous 10 (24)
PB indicates peripheral blood; CY, cyclophosphamide; FLU, ﬂudarabine; BU,
busulfan; TBI, total body irradiation.
Data presented are n (%), unless otherwise indicated.
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grade 2 toxicity. The most common regimen-related toxicity
was mucositis (21 [51%] grade 1 and 9 [21%] grade 2). Twopatients had grade 2 renal toxicity that resolved to baseline
levels, 1 patient had grade 2 hepatotoxicity that resolved, 1
patient had hepatic veno-occlusive disease that responded to
supportive care, and 1 patient had central lineerelated
subclavian vein thrombosis.
Hematopoietic Recovery
The median times to neutrophil and platelet recovery
were 17 days (range, 11 to 33) and 12 days (range, 2 to 33)
respectively. The median times to RBC and platelet trans-
fusion independence in survivors were 32.5 days (range,
0 to 1360) and 11 days (range, 0 to 373), respectively. The
upper limit of time to RBC transfusion independence was
due to 4 patients who required prolonged RBC transfusion
support, 1 due to ABO mismatch, 1 developed an acquired
factor VIII inhibitor requiring intensive care unit admis-
sion, 1 had chronic gastrointestinal bleeding due to gastric
antral vascular ectasia, and 1 developed warm autoimmune
hemolytic anemia in the absence of any GVHD signs or
symptoms. Three of these patients required RBC transfusion
support beyond 1 year.
Graft Failure
Graft failure occurred in 4 (10%) patients: 2 primary and 2
secondary. The 2 patients who had primary graft failure
received second HCTs from a second donor; 1 died of HCT-
related complications and the other is a long-term survivor.
The 2 patients who had secondary graft failure (day 64 and
day 85) received supportive care; 1 died of an intracranial
hemorrhage and the other died of sepsis. All patients who
had graft failure had failed IST before HCT.
Chimerism Data
Thirty-ﬁve (85%) patients had serial chimerism data
available, 4 had a single result, and 2 patients died before
routine testing. At 120 days after HCT, the median chimerism
level was 96% (range, 62% to 100%).
At last follow-up of the 35 patients with serial results, 21
(60%) had attained and sustained stable PDC. Seven (21%)
had stable MC with no intervention. One (3%) patient
initially attained PDC but developed secondary graft failure
and died.
GVHD
In 40 evaluable patients (1 patient died at day 3), acute
GVHD was observed in 11 (28%) patients, all grade I and II. Of
33 evaluable patients, only 6 (15%) developed chronic GVHD;
5 had mild, 1 had moderate, and none had severe chronic
GVHD. The cumulative incidences of acute and chronic GVHD
were 27% (95% conﬁdence interval [CI], 13% to 41%) and 15%
(95% CI, 4% to 27%), respectively (Figure 1A,B). GVHD did not
contribute to any of the deaths. Only 2 of 34 (6%) survivors
were on corticosteroid treatment for GVHD treatment
beyond 1 year. No patients had lung GVHD.
Infections
Culture-positive bacterial infection within the ﬁrst 100
days after HCT occurred in 21 (51%) patients and sepsis
was the primary cause of death in 2 (5%) patients. The
most commonly cultured organism was coagulase-negative
staphylococcus in 9 of the 21 (43%) patients. Bacterial infec-
tion beyond day 100 to 1 year occurred in 18 (50%) of 36
evaluable patients. The most commonly cultured organisms
were pseudomonas and coagulase-negative staphylococcus;
each cultured in 5 (28%) of the 18 patients.
Figure 1. Transplantation outcomes in aplastic anemia HCT using alemtuzumab-based conditioning. (A) Shows cumulative incidence of acute GVHD (all grades I to II).
(B) Shows cumulative incidence of chronic GVHD (all mild to moderate). (C) Shows 3-year overall survival Kaplan-Meier plot.
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patients. The median time to reactivation was 37 days
(range, 21 to 129). Seven (28%) of these patients had a
single reactivation, whereas the remaining 12 (72%) had
recurrent reactivations and none developed CMV disease.
HSV reactivation occurred in 7 (18%) of 38 evaluable pa-
tients. All of these patients responded to acyclovir. Varicella
zoster virus reactivation occurred in 10 (26%) of 38 evalu-
able patients, and 2 patients developed postherpetic neu-
ralgia. BK hemorrhagic cystitis occurred in 3 (8%) patients
and resolved in all patients. The cumulative incidences of
viral infections are presented in Figure 2A. None of the
patients developed probable or proven invasive fungal
infection.
Post-transplantation Lymphoproliferative Disorder
Three patients developed an Epstein-Barr virus (EBV)e
related lymphoproliferative disorder (PTLD) at days 72, 139,
and 167 (Table 2). Two responded to rituximab-based
treatment and 1 died because of progressive PTLD, despite
therapy. All of these patients had failed IST before HCT; 2
failed 1 course of IST and the patient who died failed 2
courses of ATG-based IST. One patient, who had a second
transplantation for primary graft failure, developed PTLD
after the second HCT. Details of these 4 cases of PTLD are
presented in Table 2 and Figure 2B.
Survival
With amedian follow-upof 3.6 years,OS at 3 yearswas85%
(Figure 1C). At time of last follow-up, a total of 7 patients died.Of these, 5 (71%) had anMSD and 2 (29%) had anMUD. One of
these patients received HCT as upfront treatment and died 3
years after HCT of an unknown cause after loss to follow-up.
The remaining 6 patients had all failed ATG-based IST before
HCT (1 failed 2 courses and 5 failed 1 course). The individual
causes of death were secondary graft failure in 2 patients
(days 137 and 199), sepsis in 2 (days 3 and 199), and PTLD in 1
(day 180). One patient died of complications of a second HCT
for primary graft failure (day 414 after the ﬁrst HCT).
In univariable analysis (including age, lines of pre-HCT
IST, HCT-CI score, Karnofsky performance score, donor,
graft source, CMV risk, and time to transplantation), age<40
years was the only factor associated with improved OS
(P ¼ .04) (Table 3). Nevertheless, 11 of the 16 (69%) patients
over 40 years are alive with an overall probability of survival
at 1 year of 67% (95% CI, 47% to 95%).Long-term Health Outcomes
We evaluated the long-term health outcomes of all the
survivors, which are summarized in Table 4. Relevant details
are below.
Lung function
Of the evaluable 33 patients, 27 had evaluable PFTs at 1
year. Of these, only 1 patient had an asymptomatic drop in
forced expiratory volume in 1 second >20%, which returned
to baseline at the second annual assessment. At last follow-
up, 27 patients had serial PFTs available for review: all had
forced expiratory volume in 1 second values similar to
baseline (Table 4).
Figure 2. Viral complications and PTLD in aplastic anemia HCT using alemtuzumab-based conditioning. (A) Shows cumulative incidence of viral infections. (B) Shows
cumulative incidence of PTLD.
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At last follow-up, 7 (21%) of the 33 survivors of the ﬁrst
HCT were requiring thyroxine replacement therapy. One
patient had a major ABO mismatched donor and was not
requiring transfusion but developed warm autoimmune he-
molytic anemia at day 404 after HCT and became transfusion
dependent, despite multiple lines of treatment. One patient
developed Guillain-Barre syndrome at day 272 after HCT and
made a full recovery after treatment with intravenous im-
munoglobulins. One patient developed an acquired factor VIII
inhibitor at day 405 after HCT. One patient developed Graves
hyperthyroidism 3.9 years after HCT that was thought to be
transplant-mediated, as the donor had a history of this.Performance Status at Last Follow-up and Return to
Work
Of the 34 survivors, only 2 patients had Karnofsky
performance scores <80%. One patient had severe autoim-
mune hemolytic anemia and required a splenectomy and the
other developed smoldering myeloma 2 years and 9 months
after HSCT, had cryptogenic fulminant hepatic failure, and
received a cadaveric liver transplant at 3 years and 10months
after HCT.Fertility
Seventeenwomenwere ages 16 to 45 years of age at time
of HCT; 2 of them died and 1 was lost to follow-up. Of the
remaining 14 women, 13 (93%) had return of their regular
menses after HCT. Six women conceived at 8, 11, 21, 22, 34,
and 89 months after HCT. Three women delivered healthy
babies, 1 is yet to deliver, and 2 had medical terminations.
Thirteen of these women were more than 1 year after
HCT and at last follow-up; 12 (92%) had normal estradiol
levels.Table 2
Post-Transplantation Lymphoproliferative Disease
Patient No. No. of lines of IST before HCT Time to HCT, mo Donor T
1 2 191 MUD 1
2 2 11 MUD
3 1 8 MSD 1
4 1 8 MUD 3
R-CHOP indicates rituximab, cyclophosphamide, doxorubicin, vincristine, and pred
* PTLD occurred on day 307 after HCT; however, this patient had a second HCTSecondary Malignancy
Only 1 long-term survivor developed a secondary ma-
lignancy: smoldering myeloma. This patient had failed 2
rounds of ATG-based IST before HCT.DISCUSSION
We report the ﬁndings of a simpliﬁed conditioning
regimen for patients with AA. Compared with previously
published studies [1,8,9,13,15,25-28], we show that an in-
termediate dose of alemtuzumab (50 to 60 mg) in combi-
nationwith high-dose cyclophosphamide or ﬂudarabine and
low-dose cyclophosphamide is effective in reducing the risk
of signiﬁcant acute and chronic GVHD, and the impact on
survival has been favorable (3-year OS of 85% in adult
patients). The rate of graft rejection is comparable to existing
studies [8,9,13,15,26-28]. As this study only involved adult
patients, the median age of 37 years is higher than previous
published reports [1,3-6,8,9].
In this study cohort, we also attempted to further
explore the detailed clinical course of patients receiving
alemtuzumab-based conditioning to identify tolerability in
older patients, infection risks, long-term health, and quality-
of-life outcomes. Patients older than 40 years old composed
39% of this study cohort, with a 1-year OS probability of 67%.
Although this appears inferior to survival of patients younger
than 40, it appears comparable or better than previously
reported studies [1,25]. The HCT-CI was previously identiﬁed
as a predictor of outcome in the study by Marsh et al. [13],
but we were not able to conﬁrm that the HCT-CI score or
performance status were predictive of outcome in this study,
likely because of the small number of patients.
There is a concern that the use of alemtuzumab is asso-
ciatedwith an increased risk of viral infection comparedwith
ATG [29,30]. Previous studies using alemtuzumab-basedime from HCT to PTLD, d Treatment of PTLD Outcome
67 1 x R-CHOP Died
72 1 x R-CHOP then 4 x rituximab Remission
39 4 x rituximab Remission
07* 4 x rituximab Remission
nisone.
on day 85 because of primary graft failure.
Table 3
Univariable Analysis for OS
Variable n (%) P Value 3-Year Survival
Probability (95% CI)
Age .041
40 25 (61) 96 (89-100)
>40 16 (39) 67 (47-95)
Lines of pre-HCT IST .084
0 20 (49) 95 (86-100)
1 11 (27) 61 (38-100)
2 10 (24) 89 (71-100)
HCT-CI .66
0-1 33 (80) 84 (72-98)
2-3 8 (20) 88 (67-100)
Performance score .10
80% 39 (95) 87 (77-98)
<80% 2 (5) 50 (13-100)
Donor 1
Matched sibling donor 29 (71) 86 (74-100)
Matched unrelated donor 12 (29) 82 (63-100)
Graft source .29
BM 34 (83) 88 (78-100)
PB 7 (17) 67 (38-100)
CMV donor/recipient .44
-/- 25 (61) 84 (70-100)
All others 16 (39) 88 (73-100)
Time to transplantation .54
6 mo 26 (63) 80 (65-97)
<6 mo 15 (37) 93 (82-100)
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EBV, and adenovirus. In this study, we tried to study the in-
fectious complications in detail and show that viral compli-
cations are common: CMV reactivation (79%), HSV (18%),
varicella zoster virus (25%), and BK virus hemorrhagic cystitis
(8%). It is noteworthy that although CMV reactivation is
common, none of the patients developed CMV disease with
screening and preemptive treatment strategies. Several novelTable 4
Long-Term Health Outcomes after Transplantation
Outcomes in Long-Term Survivors n ¼ 34
cGVHD requiring steroid therapy beyond 1 year after HCT
(evaluable ¼ 6)
2 (33)
>20% FEV1 drop from baseline at time of last follow up
(evaluable ¼ 27)
0
Autoimmune disorders
Gillian-Barre syndrome at day 272 after HCT 1 (3)
Warm autoimmune hemolytic anemia at day 404
after HCT
1 (3)
Acquired factor 8 deﬁciency at day 405 after HCT 1 (3)
Graves hyperthyroidism at 3.9 years after HCT 1 (3)
Performance score at time of last follow-up
(evaluable ¼ 34)
80% 32 (94)
<80% 2 (6)
Employment
Return to full-time work/education (evaluable ¼ 28) 25 (90)
Unable to return to work (evaluable ¼ 28) 2 (10)
Continued retirement (evaluable ¼ 7) 7 (100)
Female fertility in survivors ages 16-45 years
(evaluable ¼ 14)
Return of menses 13 (93)
Normal estradiol levels at last follow-up 12 (86)
Conceived 6 (43)
Delivered a healthy child 3
Yet to deliver 1
Terminated pregnancy 2
Secondary malignancy (evaluable ¼ 34)
Shouldering multiple myeloma 1 (3)
Data presented are n (%), unless otherwise indicated.
cGVHD indicates chronic graft-versus-host disease; FEV1, forced expiratory
volume in 1 second.effective CMV preventive strategies are on the horizon, and
hopefully integration of these strategies in alemtuzumab-
based conditioning may help in decreasing the risk of CMV
reactivation [31].
Three patients developed EBV-related PTLD and another
developed this after a second HCT. These patients had also
failed immunosuppression therapy before HCT. In a retro-
spective analysis of patients with AA who received HCT, the
strongest predictive factor for the development of PTLD was
failure to respond to repeated courses of ATG-based IST,
which suggests the need for monitoring of EBV-PCR levels in
patients who have failed IST before transplantation [32].
Long-term health outcomes using this conditioning
regimen appear to be excellent. The majority of patients had
pulmonary function that returned to baseline, regained their
performance status, and were able to return to work if pre-
viously working. In females, fertility appears to be preserved,
based on the women who were able to conceive. Preserva-
tion of fertility is an important aspect of AA transplantation,
as a large proportion of patients diagnosed with AA are
within their reproductive years. In addition to regimen-
related damage to gonads, risk of infertility is higher in
patients who get GVHD. It is plausible in our study that
prevention of signiﬁcant GVHD may have contributed to
preserved fertility.
We observed 4 patients who developed autoimmune
disorders, which, to our knowledge, has not been widely
reported. Autoimmune disease after transplantation is
becoming increasingly recognized but data are still only
based on single cases and single-center, retrospective studies
[33]. It is thought that failure of central tolerance mecha-
nisms during de novo lymphopoiesis after conditioning-
induced lymphopenia leads to the generation of new
autoreactive T and B cells and, if uncontrolled, to the devel-
opment of autoimmune disease [34]. In the setting of allo-
geneic HCT, autoimmune cytopenias are the most common
manifestations of autoimmune disease, but there is no evi-
dence linking T cell depletion as a risk factor [33]. As impli-
cated in 1 of the cases included in this study (Graves disease),
transfer of autoimmune diseases from the donor to the
recipient has also been reported [33].
There is a debate whether there should be an upper age
limit for offering an MSD as upfront therapy for SAA. In the
beginning, our center adopted the British Guidelines, and
upfront transplantation were offered to patients under the
age 40 years with an MSD [35]. Encouraged by the ability to
perform transplantation with minimal risk of signiﬁcant
GVHD, we extended the upper age limit of transplantation to
60 years as upfront therapy for those who have an MSD. Use
of SC alemtuzumab has also further simpliﬁed the protocol.
We demonstrated in this study that this protocol can be used
for related or unrelated donors, regardless of age.
In conclusion, intermediate-dose SC alemtuzumabe
based conditioning in AA is a simpliﬁed approach for con-
ditioning for AA that resulted in excellent survival and has a
favorable impact on GVHD. The majority of survivors had
good long-term health outcomes, were able to return to
work, and female fertility appears to be preserved. Never-
theless, close monitoring for viral complications, such as
CMV reactivation and EBV, particularly in patients who fail
IST before HCT, is very important.
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